Biblio

Author Title Type [ Year

]

Filters: Author is Ravandi, Farhad [Clear All Filters]

2016

Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, et al. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016.

2015

Oran B, Jimenez AM, de Lima M, Popat UR, Bassett R, Andersson B, Borthakur G, Bashir Q, Chen J, Ciurea SO, et al. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015.

Takahashi K, Kantarjian H, Garcia-Manero G, Borthakur G, Kadia T, DiNardo C, Jabbour E, Pierce S, Estrov Z, Konopleva M, et al. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk. 2015.

Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Haematologica. 2015.

Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, et al. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2015.

Sasaki K, Strom SS, O'Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Jain P, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2(5):e186-93.

2014

Ghanem H, Garcia-Manero G, Faderl S, Ravandi F, Cortes J, Katragadda L, O'Brien S, Daver N, Pierce S, Kadia T, et al. Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. Ther Adv Hematol. 2014;5(2):29-34.

2013

Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, et al. Detection of MRD may predict the outcome of patients with Philadelphia-chromosome positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013.

Strati P, Kantarjian H, Thomas D, O'Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, et al. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. 2013.

Raza A, Ravandi F, Rastogi A, Bubis J, Lim SH, Weitz I, Castro-Malaspina H, Galili N, Jawde RAbou, Illingworth A. A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure. Cytometry B Clin Cytom. 2013.

Raza A, Ravandi F, Rastogi A, Bubis J, Lim SH, Weitz I, Castro-Malaspina H, Galili N, Jawde RAbou, Illingworth A. A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure. Cytometry B Clin Cytom. 2013.

Kornblau SM, Qutub A, Yao H, York H, Qiu YHua, Graber D, Ravandi F, Cortes J, Andreeff M, Zhang N, et al. Proteomic Profiling Identifies Distinct Protein Patterns in Acute Myelogenous Leukemia CD34+CD38- Stem-Like Cells. PLoS One. 2013;8(10):e78453.

Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, York S, Ravandi F, Garris R, Kwari M, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013.

Pages